泌尿生殖系统肿瘤中的适应性免疫
本综述为非系统性协作叙述性综述,旨在描述与泌尿生殖系统肿瘤进展和治疗反应相关的关键适应性免疫生理事件。文章讨论了衰老相关免疫功能下降、肿瘤突变负荷、特定抑癌/ DNA损伤修复基因突变以及适应性免疫细胞功能状态和肿瘤免疫微环境时空定位等与免疫治疗反应不佳相关的因素。理解这些机制可能有助于开发预后和预测生物标志物,如免疫细胞浸润谱和三级淋巴结构。
要点
- 衰老相关免疫功能下降是常规和新型免疫治疗患者预后不佳的主要因素。
- 肿瘤突变负荷、KDM6A、PTEN、STAG2、TP53、ATM和BRCA2等基因突变与免疫治疗反应不佳相关。
- 免疫细胞浸润谱和三级淋巴结构(TLSs)可能与不同临床结局相关。
核心结论
- 尽管对肿瘤免疫景观中动态和静态适应性免疫元素的理解取得了巨大进展,但仍存在若干知识空白。
- 全面了解这些知识将推动精准免疫治疗、改善药物测序和治疗反应。
研究设计与样本
- 非系统性、协作性叙述性综述,旨在强调近期进展以反映当前对泌尿生殖系统肿瘤抗肿瘤适应性免疫关键介质的认识。
主要发现
- 衰老相关免疫功能下降是常规和新型免疫治疗患者预后不佳的主要因素。
- 与泌尿生殖系统肿瘤反应不佳相关的其他肿瘤免疫生物学方面包括总体肿瘤突变负荷、特定抑癌/ DNA损伤修复基因(KDM6A、PTEN、STAG2、TP53、ATM和BRCA2)突变以及适应性免疫细胞多种功能状态的丰度及其在肿瘤免疫微环境中的时空定位。
- 理解这些机制可能有助于开发预后和预测生物标志物,如免疫细胞浸润谱和三级淋巴结构(TLSs),其与不同临床结局的关联取决于新型免疫治疗方法的性质。
- 实施更新的免疫监测技术和改进的临床前建模系统将增强对导致免疫治疗反应变异性的宿主和肿瘤内在因素的理解。
局限性
- 尽管对肿瘤免疫景观中动态和静态适应性免疫元素的理解取得了巨大进展,但仍存在若干知识空白。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: While urothelial and renal cell cancers have exhibited modest responses to novel immune checkpoint inhibitors targeting the programmed death ligand 1 and its receptor, response rates in patients with prostate cancer have remained poor. The factors underlying suboptimal outcomes observed in patients treated with novel immunotherapies are still to be resolved. OBJECTIVE: To review the literature and describe the key adaptive immune physiological events associated with cancer progression and therapeutic response in genitourinary (GU) cancers. EVIDENCE ACQUISITION: We performed a nonsystematic, collaborative narrative review to highlight recent advancements leading to the current state of knowledge on the critical mediators of antitumor adaptive immunity to GU cancers. Further, we discuss the findings on the pre- and post-treatment immunological events that either are unique to each of the three cancer types or exhibit overlapping clinical associations. EVIDENCE SYNTHESIS: Aging-associated immune function decline is a major factor underlying poor outcomes observed in patients treated with both conventional and novel immunotherapies. Other cancer immunobiological aspects associated with suboptimal responses in GU cancers include the overall tumor mutational burden, mutations in specific tumor suppressor/DNA damage repair genes (KDM6A, PTEN, STAG2, TP53, ATM, and BRCA2), and abundance of multiple functional states of adaptive immune cells and their spatiotemporal localization within the tumor immune microenvironment. Understanding these mechanisms may potentially lead to the development of prognostic and predictive biomarkers such as immune cell infiltration profiles and tertiary lymphoid structures (TLSs) that associate with variable clinical outcomes depending on the nature of the novel immunotherapeutic approach. Implementation of newer immune-monitoring technologies and improved preclinical modeling systems will augment our understanding of the host and tumor intrinsic factors contributing to the variability of responses to immunotherapies. CONCLUSIONS: Despite the tremendous progress made in the understanding of dynamic and static adaptive immune elements within the tumor immune landscape, several knowledge gaps remain. A comprehensive knowledge thus gained will lead to precision immunotherapy, improved drug sequencing, and a therapeutic response. PATIENT SUMMARY: We performed a collaborative review by a diverse group of experts in the field to examine our understanding of the events and crosstalk between cancer cells and the patient's immune system that are associated with responses to novel immunotherapies. An evolving understanding of tumor-intrinsic and host-related immune alterations, both before and after therapy, will aid in the discovery of promising markers of responses to immunotherapy as well as the development of unique therapeutic approaches for the management of genitourinary cancers.
引用
- Koti M, Bivalacqua T, Black PC, et al. Adaptive Immunity in Genitourinary Cancers. Eur Urol Oncol. 2023. PMID: 37069029. doi:10.1016/j.euo.2023.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。